Sunitinib for Patients With High-Risk Renal Cell Carcinoma
Previous data showed that adjuvant sunitinib prolonged disease-free survival in patients with renal cell carcinoma at high risk of tumor recurrence after surgery compared with placebo. Michael Staehler, MD, PhD, of Ludwig-Maximilian University, Munich, presented safety and therapy management data on the use of sunitinib in the adjuvant setting at the 2017 European Society for Medical Oncology (ESMO) Congress (Abstract 855PD). The authors suggest that, if necessary, dose reductions and interruptions may help these patients to receive effective treatment.
Of the 615 patients enrolled in the S-TRAC trial, 306 were treated with sunitinib and 309 received placebo. The most common adverse events reported in the sunitinib group included palmar-plantar erythrodysesthesia, hypertension, fatigue, diarrhea, mucosal inflammation, pulmonary embolism, and neutropenia.
Treatment discontinuation due to adverse events occurred in 28.1% of the sunitinib arm and 5.9% of the placebo arm. In addition, relapse occurred in 7.2% of patients in sunitinib group and 19.4% of the placebo group. In patients treated with sunitinib, the median time to first dose reduction and dose interruption was 2.9 months and 3.0 months, respectively.